ClinicalTrials.gg
Status unknownNCT03705156Updated Apr 13, 2023

Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient

A Phase 3 interventional study of ZL-2306(nirapairb) and Placebos in Platinum-sensitive Relapsed Ovarian Cancer, sponsored by Zai Lab (Shanghai) Co., Ltd.. Status unknown at 27 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-13.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jun 2017, registered Sep 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
6th of 44
265 · median 41
Started
2017
with 3 others
Phase 3
7 of 44
none open now
Registered
15th of 44
by date
Lead sponsor
4 of 44
Zai Lab (Shanghai) Co., Ltd.

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 7 in phase 3, and was the 15th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a 2:1 randomized, double-blind, placebo-controlled, multi-center, phase III clinical study evaluating the efficacy and safety of ZL-2306 (niraparib) for maintenance treatment in patients with platinum-sensitive relapsed ovarian cancer, fallopian tube carcinoma or primary peritoneal cancer (collectively referred to as relapsed ovarian cancer).The evaluation will be divided into two stages: Stage I will be conducted in all patients, and if the predetermined statistically significant difference is not reached, the trial will continue to extend to Stage II during which evaluation will be performed in gBRCA mutation-positive ovarian cancer patients.

03

Conditions studied

  • Platinum-sensitive Relapsed Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older female.
  • High-grade serous or dominantly high-grade serous ovarian cancer
  • The subject shall have received two lines of platinum-containing chemotherapy, complete response [CR] or partial response [PR] after platinum-containing chemotherapy, and after received at least 4 cycles of platinum-containing (must be carboplatin or cisplatin or nedaplatin) in second-line platinum-containing chemotherapy.
  • (ECOG) performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Patients who have undergone ascites drainage with the last two cycles of the last chemotherapy regimen prior to enrollment.
  • Symptomatic or that have not been controlled.
  • Patients who have been diagnosed previously or currently with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    ZL-2306

    The starting dose is 300 mg or 200 mg based on patient's body weight.

    Drug: ZL-2306(nirapairb)

  • Placebo comparator
    Placebo

    The starting dose is the matched dose of placebo (3 capsules or 2 capsules).

    Drug: Placebos

Interventions

  • The starting dose is 300 mg or 200 mg based on patient's body weight.

  • DrugPlacebos

    The starting dose is the matched dose of placebo (3 capsules or 2 capsules).

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    It is defined as the time from randomization to progressive disease or death due to various causes, whichever occurs first. Progressive disease will be determined by the Independent Central Imaging Review according to standard RECIST 1.1.

    Time frame: 35 months

Secondary outcomes

  1. Chemotherapy-free interval (CFI)

    It refers to the time from the last platinum-containing treatment to the start of the next anti-cancer treatment (excluding maintenance treatment);

    Time frame: 35 months

  2. Time to first subsequent anti-cancer treatment (TFST)

    It refers to the time from the date of randomization in the study to the date when the first subsequent anti-tumor treatment starts.

    Time frame: 35 months

  3. Overall survival (OS)

    It refers to the time from the date of randomization to death for any cause.

    Time frame: 35 months

07

Study locations

27 sites
  • Cancer center of Guangzhou medical university
    Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • Harbin Medical university cancer hospital
    Harbin, Heilongjiang, China
  • the first affiliated hospital of of Harbin medical university
    Harbin, Heilongjiang, China
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Xiangya Hospital Central South Hospital
    Changsha, Hunan, China
  • Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hunan, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
  • The first Bethune Hospital of Jilin University
    Changchun, Jilin, China
  • Liaoning Cancer Hospital
    Shenyang, Liaoning, China
  • Shaanxi Cancer Hospital
    Xi'an, Shaanxi, China
  • The First Affiliated Hospital of Xi'an Jiao Tong University
    Xi'an, Shaanxi, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • West China second university hospital
    Chengdu, Sichuan, China
  • Affiliate Cancer Hospital Xinjiang Medical University
    Urumqi, Xinjiang, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan, China
  • Woman's hospital School of medicine Zhejiang University
    Hangzhou, Zhejiang, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
  • Beijing Cancer Hospital
    Beijing, China
  • Cancer hospital Chinese academy of medical science
    Beijing, China
  • Peking Union Medical College Hospital
    Beijing, China
  • Peking University People's hospital
    Beijing, China
  • Chongqing Cancer Hospital
    Chongqing, China
  • Fudan University Shanghai Cancer Center
    Shanghai, China
  • Obstetrics and Gynecology Hospital of Fudan University
    Shanghai, China
  • Tianjin Tumour Hospital
    Tianjin, China
08

References and documents

Publications

  • Wu XH, Zhu JQ, Yin RT, Yang JX, Liu JH, Wang J, Wu LY, Liu ZL, Gao YN, Wang DB, Lou G, Yang HY, Zhou Q, Kong BH, Huang Y, Chen LP, Li GL, An RF, Wang K, Zhang Y, Yan XJ, Lu X, Lu WG, Hao M, Wang L, Cui H, Chen QH, Abulizi G, Huang XH, Tian XF, Wen H, Zhang C, Hou JM, Mirza MR. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆. Ann Oncol. 2021 Apr;32(4):512-521. doi: 10.1016/j.annonc.2020.12.018. Epub 2021 Jan 14. PubMed 33453391 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Feb 2020, 31 months.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 31 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2018
First posted
Oct 15, 2018
StartActual
Jun 8, 2017
Primary completionActual
Feb 1, 2020
CompletionEst.
Aug 24, 2024
Last update
Apr 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03705156
Responsible party
Sponsor
First posted
Oct 15, 2018
Start date
Jun 8, 2017
Primary completion
Feb 1, 2020
Completion
Aug 24, 2024 (estimated)
Last update
Apr 13, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niraparib

Start the discussion